Christopher Baladad, PharmD, BCIDP's Avatar

Christopher Baladad, PharmD, BCIDP

@cbaladadpharmd

Antimicrobial stewardship pharmacist in San Diego, CA | PGY1 Penn State Hershey '21 | PGY2 ID UF Health Shands '22 | Views are my own | he/him | πŸ³οΈβ€πŸŒˆ

1,897
Followers
870
Following
19
Posts
08.11.2024
Joined
Posts Following

Latest posts by Christopher Baladad, PharmD, BCIDP @cbaladadpharmd

Post image

I love chatGPT so much for AI-generated images.

30.06.2025 22:39 πŸ‘ 3 πŸ” 0 πŸ’¬ 0 πŸ“Œ 0
Preview
Executive Summary of State-of-the-Art Review: Modern Approach to Nocardiosisβ€”Diagnosis, Management, and Uncertainties Nocardia is a genus of gram-positive, partially acid-fast bacilli that typically infect people with chronic lung disease or immunocompromised states.

Executive Summary of State-of-the-Art Review: Modern Approach to Nocardiosisβ€”Diagnosis, Management, and Uncertainties

⭐ Editor's Choice
#IDSky

24.05.2025 18:58 πŸ‘ 11 πŸ” 6 πŸ’¬ 0 πŸ“Œ 0
Post image Post image Post image

πŸ†•πŸ’« Narrative review in ICM
How to approach a patient hospitalized for pneumonia who is not responding to treatment? #idsky #EMIMCC
link.springer.com/article/10.1...

24.05.2025 20:08 πŸ‘ 10 πŸ” 2 πŸ’¬ 1 πŸ“Œ 0

Been at three different centers now with varying practices for antibiotics and ECMO. It's difficult to steward for sure.

14.05.2025 03:48 πŸ‘ 1 πŸ” 0 πŸ’¬ 1 πŸ“Œ 0

100% agree! Then at discharge we restart the clock for an additional 1-2 weeks of prolonged antimicrobials.

10.04.2025 18:24 πŸ‘ 2 πŸ” 0 πŸ’¬ 1 πŸ“Œ 0

What I wish I had right now, an already made newsletter on "Things We Do For No Reason: 'Continue IV Antibiotics While Inpatient, Then Discharge Home on Oral Antibiotics'" in patients that can otherwise tolerate oral therapy. Fewer lines, shorter stays, same outcomes. #IDSky #PharmSky

10.04.2025 17:37 πŸ‘ 7 πŸ” 0 πŸ’¬ 2 πŸ“Œ 1

For institutions that have sulbactam-durlobactam on formulary.

What are your criteria for use? Do you use it first line for all CRABs? Has it replaced high dose ampicillin-sulbactam?

#IDSky #Pharmsky

04.03.2025 18:06 πŸ‘ 2 πŸ” 0 πŸ’¬ 1 πŸ“Œ 0
Post image Post image

Important article for #AMSSky, #TxID, #UTISky, and #IDSky in @cidjournal.bsky.social:

In neutropenic & non-neutropenic cancer patients w/ & w/o catheters, the absence of nitrite/leukocyte esterase or WBC<10 had high NPV for clinically significant bacteriuria

academic.oup.com/cid/advance-...

16.01.2025 18:30 πŸ‘ 27 πŸ” 6 πŸ’¬ 2 πŸ“Œ 0

#IDSky #PharmSky Patient with M. abscessus bacteremia on iHD.

1. How are you dosing amikacin in these patients?
2. Do you have specific peak goals?
3. Do you omit amikacin entirely?

If possible, you're willing to share protocols, that'd be extremely helpful!

08.01.2025 18:50 πŸ‘ 5 πŸ” 1 πŸ’¬ 3 πŸ“Œ 0

πŸ™‹β€β™‚οΈwe have IP submit results. I was not involved in the mapping/ troubleshooting, so probably will not be helpful, but can ask my colleagues that were!

14.12.2024 00:14 πŸ‘ 1 πŸ” 0 πŸ’¬ 0 πŸ“Œ 0

I don't have experience with cefadroxil for UTIs. Though, cefazolin as the surrogate w/ cefadroxil for uUTIs had an accuracy of 91.6%. Just my interpretation is maybe you can get away with TID?

PMID: 883822; PMID: 7073267; PMID: 32659466; PMID: 32349909; PMID: 3501710

Thoughts? #IDSky #PharmSky

27.11.2024 21:56 πŸ‘ 2 πŸ” 1 πŸ’¬ 1 πŸ“Œ 0

Where do we go from here with UTI WikiGuidelines and what do you use?

This study used cephalexin @ variable doses), median txt 10d, and cefazolin MIC of <=16 as susceptible. (CLSI cut-off for uUTI).

Personally, I use cephalexin 1000 mg PO QID x10-14d if cefazolin MIC <=2 for pyelonephritis.

27.11.2024 00:25 πŸ‘ 4 πŸ” 0 πŸ’¬ 2 πŸ“Œ 0

Using posaconazole since theoretically less interactions with rifampin. Some case reports with high dose posconazole 600-800 mg daily + rifampin reached posa troughs >1.

Also thought about rifabutin 150 mg + voriconazole 200-300 mg TID based on another case report.

22.11.2024 00:30 πŸ‘ 0 πŸ” 0 πŸ’¬ 0 πŸ“Œ 0

#IDSky #PharmSky Pt w/ MTB on RIPE w/ rifampin 1200 mg QD (TDM βœ…) Smear (+) x3 mo. Now with (+) serum galactomannan (0.5) and worsening O2 status. ID wants to treat for aspergillosis. Would you start posa and continue rifampin or convert to rifabutin and start posa?

21.11.2024 19:14 πŸ‘ 5 πŸ” 0 πŸ’¬ 3 πŸ“Œ 0

πŸ“Œ

19.11.2024 02:26 πŸ‘ 0 πŸ” 0 πŸ’¬ 0 πŸ“Œ 0

Nice! Our UTI guidance document incorporates a watch and wait approach and a FAQ section with updated EBM to support not treating, but the lack of physician champion from ED and IM may be a reason for low uptake.

15.11.2024 21:59 πŸ‘ 0 πŸ” 0 πŸ’¬ 0 πŸ“Œ 0

The auditing adherence is the hard part that I’m trying to optimize rather than doing manual chart review. My previous Epic had a slicer dicer for outpatient antimicrobial prescribing where I would use it to audit durations of therapy (new Epic hasn’t validated this yet)

15.11.2024 02:45 πŸ‘ 2 πŸ” 0 πŸ’¬ 0 πŸ“Œ 0

Sadly not at my site

15.11.2024 02:19 πŸ‘ 0 πŸ” 0 πŸ’¬ 0 πŸ“Œ 0

Presented on ED abx stewardship to our new ED physician group. Highlighted our ASB treatment rates, educated on our UTI guidelines, and showed our compliance with STI screening with CDC recommendations. How do you engage your ED teams for abx stewardship? #IDsky #Pharmsky #Medsky

15.11.2024 02:02 πŸ‘ 23 πŸ” 6 πŸ’¬ 10 πŸ“Œ 0

Does your ED use Dalbavancin for SSTi? If so, what's your experience like? Is it any different from Linezolid with re: patient experience/admission/readmission/relapse/recurrence? #IDsky

10.11.2024 19:12 πŸ‘ 2 πŸ” 1 πŸ’¬ 8 πŸ“Œ 0

We're evaluating a protocol/workflow now. Prelim last line for patients that failed appropriate abx, CI to linezolid, no complicated infection, and would have been an ED obs/brief inpatient. MUE plans 12 months after rollout.

12.11.2024 18:56 πŸ‘ 1 πŸ” 0 πŸ’¬ 0 πŸ“Œ 0

Hello #PharmSky #IDSky! I’m Chris, an ID pharmacist in San Diego, passionate about antimicrobial stewardship and resistance. Looking forward to connecting and learning with everyone here!

10.11.2024 17:30 πŸ‘ 36 πŸ” 4 πŸ’¬ 7 πŸ“Œ 1

πŸ“Œ

10.11.2024 15:27 πŸ‘ 0 πŸ” 0 πŸ’¬ 0 πŸ“Œ 0